Ticagrelor Dosing in Patients <60 kg
For patients weighing less than 60 kg, ticagrelor (Brilinta) should be administered at the standard dose of 180 mg loading dose followed by 90 mg twice daily, with no dose adjustment required based on body weight alone. 1
Standard Dosing Across All Body Weights
Ticagrelor dosing does not require adjustment for low body weight (<60 kg), in contrast to prasugrel which requires dose reduction to 5 mg daily in this population. 1
The European Society of Cardiology 2020 guidelines explicitly recommend ticagrelor 180 mg loading dose followed by 90 mg twice daily for all patients with acute coronary syndrome, regardless of body weight. 1
The ACC/AHA guidelines similarly recommend standard ticagrelor dosing (180 mg loading, 90 mg twice daily maintenance) without body weight-based modifications. 2, 3, 2
Critical Distinction from Prasugrel
Prasugrel requires dose reduction to 5 mg daily (from 10 mg) in patients <60 kg due to increased active metabolite exposure and bleeding risk, but this concern does not apply to ticagrelor. 2, 3, 2, 3
Body weight <60 kg is specifically listed as a bleeding risk factor for prasugrel, but not as a contraindication or dose-adjustment criterion for ticagrelor. 2, 3
Pharmacokinetic and Pharmacodynamic Evidence
Pharmacokinetic studies demonstrate that ticagrelor exhibits linear and predictable pharmacokinetics across different body weights, with no clinically significant alterations requiring dose adjustment. 4
A 2024 consensus statement on body mass and antithrombotic therapy confirms "no change" in ticagrelor dosing for underweight patients (<18.5 BMI), maintaining the standard 90 mg twice daily dose. 5
The same consensus document notes that low body weight is a predictor of bleeding on ticagrelor, but this warrants enhanced monitoring rather than dose reduction. 5
Bleeding Risk Management in Low Body Weight Patients
While patients <60 kg have inherently higher bleeding risk on any antiplatelet therapy, this should be managed through careful monitoring and bleeding prevention strategies, not dose reduction of ticagrelor. 5, 6
Consider implementing strict gastroprotection and avoiding concomitant medications that increase bleeding risk (NSAIDs, warfarin) in low body weight patients. 2, 3
The duration of dual antiplatelet therapy may be shortened (3-6 months instead of 12 months) in high bleeding risk patients, including those with low body weight, if bleeding risk outweighs ischemic benefit. 1, 7
Essential Aspirin Dosing Consideration
- When using ticagrelor in any patient (including those <60 kg), aspirin must be limited to 75-100 mg daily, as higher doses paradoxically reduce ticagrelor effectiveness and increase bleeding. 1, 3, 6, 8
Common Pitfall to Avoid
Do not confuse ticagrelor dosing with prasugrel dosing—the 5 mg dose reduction for patients <60 kg applies only to prasugrel, not ticagrelor. 2, 1, 3
The 60 mg twice daily dose of ticagrelor exists only for long-term secondary prevention (>1 year post-MI), not for acute coronary syndrome management or based on body weight. 9